Investors

Download Presentation

Investment Highlights

We are a clinical-stage oncology company leading the development of Polynucleotide Kinase Phosphatase (PNKP) Novel Target for the Next-Generation in DNA Damage Response Inhibition

Market Size

• DNA Damage Response (DDR) Inhibitors (DDRi) represented with more than $7B in sales in 2025 (¹). • PNKP inhibitors (PNKPi) is emerging as a unique new DDRi class and ONCO is well positioned as its leader.

Market Size

• DNA Damage Response (DDR) Inhibitors (DDRi) represented with more than $7B in sales in 2025 (1). • PNKP inhibitors (PNKPi) is emerging as a unique new DDRi class and ONCO is well positioned as its leader.

Mechanism of Action

• PNKP is central to repairing DNA strand breaks and damaged DNA bases. • PNKPi sensitizes cancers to DNA damaging agents and exploits common synthetic lethal partners

Mechanism of Action

• PNKP is central to repairing DNA strand breaks and damaged DNA bases. • PNKPi sensitizes cancers to DNA damaging agents and exploits common synthetic lethal partners

Lead Program

• Preclinical efficacy with no observed toxicity in early animal studies. • Advancing toward first-in-human trials in 2026

Lead Program

• Preclinical efficacy with no observed toxicity in early animal studies. • Advancing toward first-in-human trials in 2026

Intellectual Property

• Exclusive rights to all PNKPi foundational patents Inhibitors + Nanoparticle Delivery + Synthetic Lethality

Intellectual Property

• Exclusive rights to all PNKPi foundational patents Inhibitors + Nanoparticle Delivery + Synthetic Lethality

AI-native Accelerated Approach

• Leveraging PNKPi specific data & models to reduce the time, cost and risk of clinical efforts & expand our IP & pipeline

View Press Release

AI-native Accelerated Approach